Chronic hepatitis B is a refractory disease with a low clinical cure rate and the only way to maintain disease stability is through long-term antiviral therapy. Recent guidelines from the American Academy of Liver Diseases (AASLD), the European Academy of Liver Diseases (EASL), the Asia Pacific Society of the Liver (APASL) and the National Health Insurance System (NICE) all point out that antiviral therapy for chronic hepatitis B is the closest to a cure if it achieves negative surface antigen (HBsAg) or seroconversion, and that cirrhosis and hepatocellular carcinoma are significantly less likely to occur if HBsAg is negative or seroconverted. The chances of cirrhosis and liver cancer are significantly reduced, and the quality of life and life expectancy are similar to those of normal people. However, the chances of HBsAg negative conversion or seroconversion or seroconversion with the current clinical antiviral treatment regimen are extremely low. In order to improve the clinical cure rate of chronic hepatitis B and remove China’s “hepatitis power”, the 12th Five-Year Plan was established by the Ministry of Science and Technology and the Health and Family Planning Commission under the direct supervision of the State Council. The study is led by the First Hospital of Zhejiang University, and 10 large hospitals in China are participating in the study. The Department of Infection of Wuhan Union Medical College Hospital has started the study as a cooperative unit. Patients who are eligible and enrolled will receive: 1. free antiviral treatment for one year 2. full follow-up for one and a half years 3. fee waiver for some laboratory tests Patients who meet the following conditions (1) and (2) or (1) and (3) are eligible to apply: 1. HBsAg positive with a disease duration of more than six months; 2. no antiviral history, HBeAg positive with ALT ≥ 2 times the upper limit of normal value or Liver biopsy with inflammation above G2 and HBV DNA ≥ 2×104 IU/mL; 3. On antiviral therapy with nucleoside analogues (except for tibivudine), HBeAg negative, anti-HBe positive, HBV DNA <20 IU/mL, normal ALT and consolidation of therapy for more than six months. Patients volunteering for the study should contact: Dr. Hu Email: [email protected] Dr. Li Email: [email protected] Eligible patients should send their personal information to the above email address and attach their most recent liver function, "two-and-a-half" and HBV DNA test results and dates. 2014-6-21 Wuhan Union Medical College Hospital, Department of Infection "Surface Antigen Negative" Group